Oxford BioTherapeutics Announces Third Oncology Drug Candidate from Boehringer Ingelheim Collaboration Selected to Advance into IND-Enabling Studies
Oxford BioTherapeutics Announces Third Oncology Drug Candidate from Boehringer Ingelheim Collaboration Selected to Advance into IND-Enabling Studies GlobeNewswire July 03, 2025 Drug candidate is one of several oncology assets approaching or in clinical development, discovered through Oxford BioTherapeutics' proprietary OGAP(R)-Verify discovery platform OBT receives milestone payment associated with advance of drug candidate Oxford, UK and […]